A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL

Abstract

Methods: The biomarker evaluable population (BEP) included 211 pts in POPLAR (ITT=287) and 583 pts in OAK (excludes pts with known EGFR/ALK mutations; ITT=850), with blood samples available for targeted genomic sequencing. The bTMB assay interrogates single nucleotide variants (SNVs) in 394 genes from cell-free DNA in plasma and reports a score based on the number of high-confidence SNVs identified. The BEP was grouped by bTMB cut points based on the minimum number of SNVs present.